Drugs that contain Pemetrexed Disodium
1. Alimta patents expiration
ALIMTA's oppositions filed in EPO
ALIMTA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5344932 | LILLY | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5344932 (Pediatric) | LILLY | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
Jan, 2017
(7 years ago) | |
| US7772209 | LILLY | Antifolate combination therapies |
Nov, 2021
(2 years ago) | |
|
US7772209 (Pediatric) | LILLY | Antifolate combination therapies |
May, 2022
(1 year, 10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-571) | Sep 26, 2011 |
| New Indication(I-601) | Jul 02, 2012 |
| M(M-122) | Oct 17, 2015 |
| M(M-61) | Mar 17, 2014 |
| Pediatric Exclusivity(PED) | Sep 17, 2014 |
Market Authorisation Date: 07 September, 2007
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of ALIMTA before it's drug patent expiration?
More Information on Dosage
ALIMTA family patents
2. Pemetrexed patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11147817 | SHILPA | Pharmaceutical composition of pemetrexed |
Mar, 2035
(10 years from now) | |
Market Authorisation Date: 22 May, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
PEMETREXED family patents